Robert Petersen Email & Phone Number

Indianapolis, In, Us

Indianapolis, Indiana, Us

Dublin, Ie

Led the ICON BD and operational account teams to major successes at assigned accounts Lilly, Teva, GSK, Astellas, Shire and AbbVie through coordinated selling & crossfunctional teamwork.• Owned, created, and drove account strategies and orchestrated the efforts of spirited, cross-functional account teams to engage sponsors, address issues, and close sales opportunities.• Achieved 145+% to target and $50M+ in booked annual new business wins.• Converted Teva, Lilly, and Astellas from Tier 2 to global alliance accounts by leading account teams to develop and execute diverse long-term strategies and bid defense meeting tactics.• Served as Alliance Leader for GSK and Lilly. Engaged the executive sponsors, led governance processes, identified and resolved study implementation problems, and rapidly addressed client requests.2015 - Delivered consulting services for global biopharmaceutical brand development and clinical development organizations.

Boston, Ma, Us

Led the inVentiv Health relationship with Eli Lilly and other Midwest pharmaceutical and biotech strategic partnership clients in this business development (BD) and alliance management role. Built relationships with key senior leaders in strategic alliance accounts to understand client business goals and related global services needs. Developed and led a global cross-business unit team of operational and BD professionals to expand client knowledge and sell inVentiv Health services.CRO- Clinical Development: Exceeded revenue growth targets on $140+ million base through exceptional operational performance, yielding organic growth and business development wins.Advertising/ PR/ Sales/ Patient Adherence/ Consulting: $100+ million segment. Organized and coordinated BD and alliance management activity with client global and US business units.• Awarded new advertising agency of record (AOR) business for 5 major new Lilly diabetes and oncology brands, transitioning from 3 blockbuster AOR brands going off patent.• Won new business with zero footprint business units: 2 new sales forces, cardiology brand naming, consulting for oncology launch brands, eCommerce digital strategy, biosimilars PR.

Indianapolis, In, Us

As a BioCrossroads consultant, developed the official Indiana Health Information Technology Inc. (IHIT) Strategic and Operational Plan to expand health information exchange (HIE) in Indiana. IHIT conducted six multi-million dollar projects to expand interoperability and “meaningful use” healthcare provider information sharing.Led the 25-member State of Indiana, BioCrossroads, and HIE company project team to write an application, submit for, and be awarded a $10.3 million federal HITECH grant.Produced “From Dishwashers to Digital Medical Records: Indiana’s Leadership in Health Information Technology,” an analysis of the economic impact of 72 Indiana HIT companies. Describes Indiana’s health information exchange organizations and forces driving HIT innovation and expansion.

Indianapolis, Indiana, Us

Launched Lean Six Sigma with the 1,500+ employees of GBD, global regulatory affairs, global patient safety, and project management. Produced over $42 million in Income Before Tax savings and 30-50% reductions in key process cycle time by eliminating waste, reducing cost, and improving cycle times. Created greater customer satisfaction through 250 Black Belt Lean Six Sigma & Kaizen projects.Grew leadership and career effectiveness skills in 22 Black Belt direct reports and indirectly in 6 Master Black Belts (MBBs) and 60 other LRL Black Belts.Created an external community of 20 global professional societies’ leaders to establish the scientific foundation of what is known about co-morbid diabetes and depression. Identified gaps in science and clinical practice, and created an action plan of new scientific research, clinical care model development, and community support.

Indianapolis, Indiana, Us

Developed, registered and launched five new indications, including idiopathic short stature and short stature caused by Turner syndrome; SHOX gene deficiency approval pending. Designed and launched new HumatroPen injection devices with alliance partner Ypsomed. Led business development to in-license Alkermes AIR inhalation technology and established a Lilly/Alkermes inhaled hGH development program. Also led business development and alliance management activities with Esoterix to develop and commercialize a SHOX genetic deficiency biomarker test used to diagnose a form of short stature.As General Manager of this $430 million global human growth hormone (hGH) business, tripled kilogram sales and doubled dollar sales, achieving number two global market share. Built and led a 70 member cross-functional product team to develop and execute a new global Humatrope life cycle strategy. Managed a $25 million annual team project budget. Coordinated US, Europe, and Japan strategy implementation by clinical development teams, marketing leaders, and over 400 specialty sales reps.

Indianapolis, Indiana, Us

• Lilly Germany Marketing and Sales Director and Primary Care and Neuroscience Business Unit Director• US Pharmaceutical Division HR director- management development, succession planning, and operational HR• US Prozac marketing plans manager- designed and implemented marketing, sales campaigns• Other US and international marketing and sales leadership roles, including Select Products marketing plans manager, Lilly district sales manager- Charlotte NC, international Humulin, Oncovin, and Dobutrex marketing plans manager, US Nebcin, Mandol, and Tazidime marketing plans associate, diabetes and cardiovascular new product planning associate, Lilly sales representative- Culver City CA, and injectable antibiotics market research associate• Therapeutic areas include diabetes, endocrinology, neuroscience, oncology, cardiology, anti-infectives, gastroenterology, pain and inflammation management

Master Of Business Administration (M.B.A.), Marketing, Finance

Bachelor'S Degree, Economics

Education record